Where does Orofino Pharmaceuticals Group S.R.L. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Orofino Pharmaceuticals Group S.R.L. ranks #36,848 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Orofino Pharmaceuticals Group S.R.L. hold?

Orofino Pharmaceuticals Group S.R.L. holds 7 US utility patents granted between 2019 and 2025, spanning 8 technology areas.

What is Orofino Pharmaceuticals Group S.R.L.'s Innovation Score?

Orofino Pharmaceuticals Group S.R.L. has an Innovation Score of 22.4 out of 100 (10th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Orofino Pharmaceuticals Group S.R.L.'s patent grant rate increasing or decreasing?

Orofino Pharmaceuticals Group S.R.L.'s recent grant velocity is +0% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Orofino Pharmaceuticals Group S.R.L.'s patents?

Orofino Pharmaceuticals Group S.R.L.'s patents average 6.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Orofino Pharmaceuticals Group S.R.L. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Orofino Pharmaceuticals Group S.R.L.

Q: What technology areas does Orofino Pharmaceuticals Group S.R.L. focus on?

Orofino Pharmaceuticals Group S.R.L.'s top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 3 patents. Grants appear in 8 CPC subclasses total.

USPTO PatentsView assignee record - 7 granted patents across 8 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Orofino ranks #36,848 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 8 technology areas.

#36,848
of 49,997 US assignees by volume: 10th percentile
by Innovation Score (22.4/100): 6.4
avg claims per patent: +0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R36848 · Foreign Corporation #36,848 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-SPARSE · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

GRANTS-MICRO 7 grants
MID-PACK #36,848/49,997
PHOTO-FINISH Orient Chemical…
CPC-NARROW A61M · 8 areas
INNOV-THIN 22.4/100
CLAIMS-SPARSE 6.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-FLAT +0% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Orient Chemical Industries Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Orofino Pharmaceutic… · this assignee

22
3D Lighting… · lowest

7

What this shows Orofino's Innovation Score is 22.4/100 (10th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Orofino's grants concentrate

Orofino Pharmaceuticals Group S.R.L. is a focused PatentsView assignee: 8 CPC subclasses with 42.9% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2019 (3 grants) versus a trough of 1 in 2023. By volume, Orofino sits between Orient Chemical Industries Co., Ltd. and Osaka Prefectural Hospital Organization.

Orofino's three-year grant acceleration

Orofino Pharmaceuticals Group S.R.L. shows 1 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Orient Chemical I…

7
Oriental Union Ch…

7
Orion Engineered…

7
Orlando Health

7
Orthorebirth

7
Osaka Electro-com…

7
Osaka Municipal T…

7
Osaka Prefectural…

7
Orofino Pharmaceu… ◀

7

What this shows Orofino holds 7 patents at rank #36,781, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Orofino

By rank, the assignees closest to #36,781 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Orofino's primary technology class.

Orofino's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

22 10th percentile higher than 10% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Orofino Pharmaceuticals Group S.R.L. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	3	42.9%
2021	2	28.6%
2023	1	14.3%
2025partial year	1	14.3%

Which technologies does Orofino Pharmaceuticals Group S.R.L. patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 3

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 3

B32B - Layered Products, i.e. Products Built-up OF Strata OF Flat OR Non-flat, e.g. Cellular OR Honeycomb, Form 1

A47J - Kitchen EQUIPMENT; Coffee MILLS; Spice MILLS; Apparatus FOR Making Beverages 1

B65D - Containers FOR Storage OR Transport OF Articles OR Materials, e.g. Bags, Barrels, Bottles, Boxes, Cans, Cartons, Crates, Drums, Jars, Tanks, Hoppers, Forwarding CONTAINERS; Accessories, Closures, OR Fittings THEREFOR; Packaging ELEMENTS; Packages 1

A23L - Foods, Foodstuffs OR Non-alcoholic Beverages, NOT Otherwise Provided FOR; Preparation OR Treatment Thereof 1

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 1

B65B - Machines, Apparatus OR Devices FOR, OR Methods OF, Packaging Articles OR MATERIALS; Unpacking 1

Top 8 of 8 technology areas

Where it ranks

Overall rank by patents

#36,848

of 49,997 tracked assignees

Innovation Score

22.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Orofino Pharmaceuticals Group S.R.L.'s patent record in context - here's where to go next.

Orofino Pharmaceuticals Group S.R.L.'s lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 42.9% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #36,848 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Orofino Pharmaceuticals Group S.R.L. against Orient Chemical Industries Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 22.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.